Shivani M. Desai

Pune, MH, India

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 28 publications

Therapeutic Potential of Mesenchymal Stem Cells or their Secretome in Diabetic Mice with or without Preconditioning Treatment.

Therapeutic Potential of Mesenchymal Stem Cells or their Secretome in Diabetic Mice with or without Preconditioning Treatment.

Journal: Recent advances in inflammation & allergy drug discovery
Published: July 26, 2024

WITHDRAWN: Role of Biomarkers for Diagnosis and Prediction in Type 1 Diabetes: An Overview

WITHDRAWN: Role of Biomarkers for Diagnosis and Prediction in Type 1 Diabetes: An Overview

Journal: Current drug discovery technologies
Published: March 27, 2024

Curious Case of a Giant Retroperitoneal Cyst.

Curious Case of a Giant Retroperitoneal Cyst.

Journal: Cureus
Published: January 06, 2024

A randomized, active-controlled, multi-centric, phase-II clinical study to assess safety and immunogenicity of a fully liquid DTwP-HepB-IPV-Hib hexavalent vaccine (HEXASIIL®) in Indian toddlers.

A randomized, active-controlled, multi-centric, phase-II clinical study to assess safety and immunogenicity of a fully liquid DTwP-HepB-IPV-Hib hexavalent vaccine (HEXASIIL®) in Indian toddlers.

Journal: Vaccine
Published: November 08, 2023

Effects of Mesenchymal Stem Cell-conditioned Media with Natural Immunomodulatory Agent Resveratrol on Type 1 Diabetes.

Effects of Mesenchymal Stem Cell-conditioned Media with Natural Immunomodulatory Agent Resveratrol on Type 1 Diabetes.

Journal: Current drug discovery technologies
Published: October 03, 2023

A Snapshot of Biomarkers in Psoriasis.

A Snapshot of Biomarkers in Psoriasis.

Journal: Current drug discovery technologies
Published: September 18, 2023

Safety and immunogenicity of SIIPL Tdap, a new tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, in healthy subjects 4-65 years of age: A Phase II/III randomized, observer-blinded, active controlled, multicenter clinical study in Germany.

Safety and immunogenicity of SIIPL Tdap, a new tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, in healthy subjects 4-65 years of age: A Phase II/III randomized, observer-blinded, active controlled, multicenter clinical study in Germany.

Journal: Vaccine
Published: July 24, 2023

Immunogenicity and safety of a new quadrivalent HPV vaccine in girls and boys aged 9-14 years versus an established quadrivalent HPV vaccine in women aged 15-26 years in India: a randomised, active-controlled, multicentre, phase 2/3 trial.

Immunogenicity and safety of a new quadrivalent HPV vaccine in girls and boys aged 9-14 years versus an established quadrivalent HPV vaccine in women aged 15-26 years in India: a randomised, active-controlled, multicentre, phase 2/3 trial.

Journal: The Lancet. Oncology
Published: May 02, 2023

A phase-I, open label clinical trial to assess the safety & tolerability of qHPV vaccine manufactured by Serum Institute of India Pvt. Ltd. in adults.

A phase-I, open label clinical trial to assess the safety & tolerability of qHPV vaccine manufactured by Serum Institute of India Pvt. Ltd. in adults.

Journal: Vaccine: X
Published: April 12, 2023

A phase III randomized-controlled study of safety and immunogenicity of DTwP-HepB-IPV-Hib vaccine (HEXASIIL®) in infants.

A phase III randomized-controlled study of safety and immunogenicity of DTwP-HepB-IPV-Hib vaccine (HEXASIIL®) in infants.

Journal: NPJ vaccines
Published: March 24, 2023

Safety and immunogenicity of an indigenously developed tetanus toxoid, diphtheria toxoid, and acellular pertussis vaccine (Tdap) in adults, adolescents, and children in India.

Safety and immunogenicity of an indigenously developed tetanus toxoid, diphtheria toxoid, and acellular pertussis vaccine (Tdap) in adults, adolescents, and children in India.

Journal: Expert review of vaccines
Published: March 08, 2023

A Phase I study to evaluate safety and tolerability of DTaP-IPV + Hib vaccine in healthy adult volunteers in India.

A Phase I study to evaluate safety and tolerability of DTaP-IPV + Hib vaccine in healthy adult volunteers in India.

Journal: Vaccine: X
Published: December 19, 2022
Showing 1-12 of 28

Last Updated: 09/26/2026